This blog was written by Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. It was apparently random, although I secretly suspect it was karmic punishment for my lack of imagination in writing the

This post was written by Ros Deegan, President and CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In May 2007, I trekked to Everest Base Camp in Nepal. Situated at an altitude of over

This blog is written by Samantha Truex, Atlas EIR and CEO of a stealth-stage biotech, as part of the From The Trenches feature of LifeSciVC. In a 2014 analysis  of biotech boards and a reprise analysis in 2016, Bruce Booth

At the end of every year, we host both our Atlas Venture Annual Meeting for our fund investors (Limited Partners) and our Atlas Retreat for senior industry executives.  As a kickoff for these two meetings, we typically open with a

Over the past six years, the biotech sector has experienced an incredible run of IPOs, reflecting the longest and largest “open window” for new offerings. Much has been written about post-IPO performance here and elsewhere, but there’s been little discussion

This post was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. Today I will continue my time-honored January tradition of an optimistic blog post providing some bold predictions for the

This blog was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC Biotech is an industry that calls for leaders. It requires people who are willing to take risks, conquer new science,

2018 was a gangbuster year for VC-funding into startups, reaching levels not seen since the height of the dot-com and genomics era. According to recent data from the NVCA/Pitchbook, VC across all sectors topped $130B invested across nearly 9000 deals

Another year, another JPM week. With a weekend to recuperate and reflect, I come away more concerned than ever about JPM and our industry. For context, by JPM I don’t mean the actual J.P. Morgan Healthcare Conference at the Westin

2018 was a incredible boom year in the number of new biotech offerings, with 60 IPOs on US exchanges. But as we’re all painfully aware, after the overall biotech market ($XBI) touched its all-time high in August, the last third

This blog was written by Jason Gardner, CEO of Magenta Therapeutics and Liverpool soccer fan, as part of the From The Trenches feature of LifeSciVC. Nine presentations, three press releases, forty-two satellite meetings. One conference. Most biotech companies have that

This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC. The evening of April 26, 2009, I walked from my hotel room to the nearest bar. The bar was